lenvatinib Mesylate
|
- ₹9093
- Product name: lenvatinib Mesylate
- CAS: 857890-39-2
- MF: C22H23ClN4O7S
- MW: 522.95862
- EINECS:812-398-0
- MDL Number:MFCD18633219
- Synonyms:lenvatinib Methanesulfonate;E7080 Mesylate;4-[3chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate;lenvatinib Mesylate;CAT#A863437;Lenvatinib Mesylate,Amadis Chemical offer CAS#857890-39-2;E7080;E-7080;E 7080;maltitol E:candyli(at)speedgainpharma(dot)com
1 prices
Selected condition：
Brand
- Sigma-Aldrich(India)
Package
- 10MG
- ManufacturerSigma-Aldrich(India)
- Product numberSML3017
- Product descriptionLenvatinib mesylate ≥98% (HPLC)
- Packaging10MG
- Price₹9093
- Updated2022-06-14
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | SML3017 | Lenvatinib mesylate ≥98% (HPLC) | 10MG | ₹9093 | 2022-06-14 | Buy |
Properties
Melting point :>220°C (dec.)
storage temp. :-20°C Freezer
solubility :DMSO (Slightly), Methanol (Slightly)
form :Solid
color :White to Off-White
InChIKey :HWLFIUUAYLEFCT-UHFFFAOYSA-N
SMILES :O=C(N)C1C=C2C(N=CC=C2OC2C=C(Cl)C(NC(=O)NC3CC3)=CC=2)=CC=1OC.CS(=O)(O)=O
storage temp. :-20°C Freezer
solubility :DMSO (Slightly), Methanol (Slightly)
form :Solid
color :White to Off-White
InChIKey :HWLFIUUAYLEFCT-UHFFFAOYSA-N
SMILES :O=C(N)C1C=C2C(N=CC=C2OC2C=C(Cl)C(NC(=O)NC3CC3)=CC=2)=CC=1OC.CS(=O)(O)=O
Safety Information
| Symbol(GHS): |
|
|||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | |||||||||||||||||||||||||||||||||||
| Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
| Precautionary statements: |
|
Description
Lenvatinib mesylate (lenvatinib) is an oral targeted therapy medicine known as a receptor‐type tyrosine kinase inhibitor. It is a small-molecule drug (a drug that can enter cells easily), which was developed at Eisai in 2015. It was approved by the FDA in 2015 for the treatment of differentiated thyroid cancer that is either locally recurrent, metastatic, or progressive and did not respond to radioactive iodine treatment. In May 2016, the FDA approved the drug as a combination therapy with everolimus for the treatment of advanced renal cell carcinoma. Because VEGF (and fibroblast growth factor receptors, known as FGFRs) are thought to play a role in cardiovascular signaling pathways, VEGF2R and FGFR inhibition are thought to be the mechanisms behind the primary side effect of lenvatinib mesylate, which is hypertension.More related product prices
Lenvatinib 4-chloro-7-Methoxyquinoline-6-carboxaMide 4-Amino-3-chlorophenol Methyl 4-chloro-7-Methoxyquinoline-6-carboxylate Methyl 7-Methoxy-4-oxo-1,4-dihydroquinoline-6-carboxylate 52671-64-4 Olaparib Nintedanib Ethanesulfonate Salt 918504-65-1 PLERIXAFOR Afatinib (BIBW 2992) Crizotinib Dacomitinib (PF299804)Related product price
- 52671-64-4
₹4514.03-12700 - PLERIXAFOR
₹4800-13800 - Crizotinib
₹13174.03